IGC — IGC Pharma Income Statement
0.000.00%
Last trade - 00:00- $28.48m
- $28.21m
- $1.27m
Annual income statement for IGC Pharma, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.898 | 0.397 | 0.911 | 1.34 | 1.27 |
| Cost of Revenue | |||||
| Gross Profit | 0.113 | 0.194 | 0.442 | 0.733 | 0.619 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 9.79 | 15.9 | 12.5 | 14.5 | 8.72 |
| Operating Profit | -8.89 | -15.5 | -11.6 | -13.1 | -7.45 |
| Gain / Loss on Sale of Assets | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.81 | -15 | -11.5 | -13 | -7.12 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.81 | -15 | -11.5 | -13 | -7.12 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.81 | -15 | -11.5 | -13 | -7.12 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.81 | -15 | -11.5 | -13 | -7.12 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.206 | -0.238 | -0.212 | -0.148 | -0.09 |